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Luisa Giaccone,1 Moreno Festuccia,1 Andrea Marengo,2 Isabel Resta,1 Roberto Sorasio,1
Fabrizia Pittaluga,3 Francesca Fiore,1 Mario Boccadoro,1 Mario Rizzetto,2
Benedetto Bruno,1 Alfredo Marzano2Patients previously infected with hepatitis B virus (HBV) undergoing an allograft and recipients from HBV
carrier donors are at risk of posttransplant viral reactivation. The role of prophylaxis with lamivudine remains
unclear. One hundred seventeen patients, with a median age of 52 years (20-67 years), with various hemato-
logic malignancies transplanted between 1999 and 2007 entered the study. Eighty-seven recipients negative
for HBV surface antigen (HBsAg), antihepatitis B core antigen antibodies (anti-HBc), and HBV-DNA with
HBsAg and HBV-DNA negative donors were defined as at low risk of HBV reactivation, whereas all the
remaining 30 patients were defined as at high risk. Patients at high risk transplanted in 2005 or after received
lamivudine to prevent HBV reactivation as per the Italian guidelines by the Associazione Italiana per lo Studio
del Fegato (AISF). Patients at low risk did not experience HBV reactivation/hepatitis. Among the recipients at
high risk, 11 of 25 anti-HBc positive, those HBsAg positive (2 of 2) or negative but transplanted from HBsAg
positive donors (3 of 3) were treated with lamivudine. None of these developed HBV reactivation/hepatitis
after a median follow-up of 40 months (17-55 months). Hepatitis developed in 3 anti-HBc positive untreated
patients conditioned with a reduced-intensity regimen. Hepatitis B was not observed in recipients at low risk,
transplanted fromHBsAg negative/anti-HBc positive or negative donors. Lamivudine was effective in control-
ling reactivation in: HBsAg positive recipients, in patients transplanted from HBsAg positive donors and in
HBsAg negative/antiHBc positive recipients, who showed a significant risk of reactivation if not given prophy-
laxis (NCT 00876148).
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Hepatitis B virus (HBV) reactivation after
allogeneic stem cell transplantation (SCT) is a well-
known complication not only in HBV surface antigen
(HBsAg) carriers, but also in patients with resolved
HBV infection [1]. Furthermore, for HBV negative re-
cipients, donors not previously exposed to HBV infec-
tion are generally preferred toHBsAg positive orHBVDivision ofHematology; 2DivisionofGastro-Hepatology;
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6/j.bbmt.2009.12.533exposed donors [2]. Although poorly characterized,
the mechanisms through which the reactivation of
latent viral infection occurs is likely to involve a 2-stage
process [3]. First, it is widely assumed that in recipients
of an allograft previously exposed to HBV, the im-
paired cellular immunity because of the underlying
disease and its treatments can cause viral replication
that may lead to fulminant hepatitis. The second stage
occurs following the withdrawal of the cytotoxic or
immunosuppressive agents and the restoration of
the immune function that may result in the T cell
immune-mediated destruction of the infected hepato-
cytes. This phase of immune-reconstitution is usually
characterized by clinical hepatitis with transient eleva-
tion of alanine aminotransferase (ALT), possible jaun-
dice, and development of constitutional symptoms.
The management of HBV in allogeneic transplan-
tation has changed after the introduction in clinical
practice of nucleoside analogs such as lamivudine,
capable of inhibiting HBV replication and of reducing
viral load. Recently, lamivudine has been administered809
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[4-7]. However, its role is still controversial with
regard to: (1) prophylaxis in HBsAg negative patients
with antibodies against HBV core antigen (anti-
HBc), (2) risk of posttransplant hepatitis from HBsAg
positive or anti-HBc positive donors, (3) optimal dura-
tion of lamivudine prophylaxis, and (4) possible occur-
rence of drug resistance.
Most published studies on posttransplant HBV
reactivation/hepatitis refer to transplants following
conventional myeloablative conditioning regimens,
whereas reduced-intensity conditioning (RIC)/non-
myeloablative (NMA) conditioning regimens have
increasingly been used in the past 5-10 years. There-
fore, less toxic conditioning regimens are currently
more commonly offered to heavily pretreated or
older patients with comorbidities. However, the risk
of HBV reactivation has not been fully evaluated
yet in medically unfit patients [8,9].
Here, we report our experience on HBV reactiva-
tion and on the use of lamivudine as prophylaxis in pa-
tients considered at risk of HBV reactivation (NCT
00876148).DESIGN AND METHODS
Patients
One hundred seventeen Caucasian patients who
underwent an allograft between 1999 and 2007 at the
Bone Marrow Transplant Unit of the University of
Torino, Torino, Italy, were included in this retrospec-
tive study. Another 6 patients were excluded because
HBV serology was not available. Patient characteris-
tics are summarized in Table 1. Eighty-six transplants
were from an HLA-identical sibling donor and 31
fromanunrelated donor.Three patients received a sec-
ond allograft from the same donor for disease progres-
sion and were included in the study since the first
allograft.
As part of the pretransplant workup, all patients
and donors were evaluated, within 1 month from
transplant, for presence of HBsAg, antibodies
against HBsAg (anti-HBs), anti-HBc, hepatitis C vi-
rus (anti-HCV); hepatitis B e antigen (HBeAg) and
antibodies against HBeAg (anti-HBe), and hepatitis
D virus (anti-HDV) in HBsAg positive individuals;
serum HBV-DNA (COBAS Amplicor HBV Moni-
tor Test, Roche Diagnostics, Switzerland; threshold
level 60 IU/mL up to June 2005; COBAS Ampli-
Prep/COBAS TaqMan HBV Test, threshold level
12 IU/mL from July 2005 onward) was invariably
evaluated at baseline in all patients and donors.
Liver function tests (LFT) included ALT (reference
values 8-40 UI/L), aspartate aminotransferase (AST)
(reference values 8-40 UI/L), gamma-glutamyl
transpeptidase (reference values 10-50 UI/L),alkaline phosphatase (reference values 53-128 UI/
L), total (reference values 0.2-1.01 mg/dL), and
fractionated bilirubin, prothrombin time (Interna-
tional Normalized Ratio), partial thromboplastin
time, fibrinogen, D-dimer, and antithrombin. All
tests were performed with commercially available kits
(AUSRIA II and HBe Kit; Abbott Laboratories, North
Chicago, IL; AB AUK 3, Sorin Biomedica, Saluggia,
VC, Italy; Ortho Diagnostic System, Milan, Italy).
Given the Caucasian origin of all the HBsAg positive
donors and recipients included in the study, the
absence of pretransplant chronic liver disease and of
previous treatments with nucleoside or nucletide ana-
logs, HBV genotype and mutants were not evaluated
in accordance with our national guidelines [7,10,11].
The study was approved by the institutional review
board of our Institution (NCT 00876148).Risk Categories and Lamivudine Prophylaxis
The recipients negative for serum HBsAg, anti-
HBc, and HBV-DNA who were transplanted from
HBsAg and HBV-DNA negative donors (regardless
of their anti-HBc status) were defined as ‘‘naı¨ve’’ and
considered at low risk of posttransplant HBV
reactivation/hepatitis. HBV reactivation has been
reported in this group [12,13]; however, in our study,
they were defined as naı¨ve given that recipients who
lack HBV serum markers are infrequently carriers of
an occult HBV infection, which is likely to reactivate
[13]. For the same reason, HBsAg and HBV-DNA
negative donors are very unlikely to transmit the infec-
tion, whereas the rate of HBV transmission from anti-
HBc-positive donors of solid organs, different from
the liver, is very low [7,14]. Low-risk patients did not
receive any HBV prophylaxis throughout the study.
All HBV carriers defined as HBsAg positive and/or
anti-HBc positive recipients, or recipients with HBsAg
positive donors, regardless of the presence/absence of
other HBV serum markers, were regarded as at high
risk of HBV reactivation. Overall, 14 anti-HBc positive
recipients transplanted in 2004 or before (phase 1) did
not receive any prophylaxis (Table 2) whereas, when
transplanted in 2005 or later (phase 2), in light of the rec-
ommendationsby theAssociazione Italianaper loStudio
del Fegato (A.I.S.F.) [7], anti-HBc positive recipients
were treated with lamivudine. Overall, of the 61 recipi-
ents transplanted in phase 2, 16 (2HBsAg positive recip-
ients, 3 HBsAg negative recipients with HBsAg positive
donors and 11HBsAg negative/anti-HBcpositive recip-
ients) received lamivudine prophylaxis.
Lamivudine was given at 100 mg/day from con-
ditioning up to 12-18 months after discontinuation
of all immunosuppressive drugs [7,15]. Patients
off immunosuppression but on chemotherapy for
disease relapse were maintained on lamivudine
prophylaxis.
Table 1. Patient characteristics
No. of patients 117
Median age at transplant, years (range) 52 (20-67)
Median follow-up, months (range) 42 (14-111)
Male/Female 55/62
Disease
Multiple myeloma 61
Acute myelogenous leukemia/RAEB 18
Chronic lymphocytic leukemia 14
Lymphoma 15
Chronic myeloproliferative disease 7
Chronic myelomonocytic leukemia 1
Aplastic anemia 1
Conditioning regimens
Conventional
Cyclophosphamide-TBI (1200 cGy) 6
Busulfan-Cyclophosphamide 8
Cyclophosphamide-ATG 1
Reduced intensity
Thiothepa-Cyclophosphamide 16
Melphalan-Fludarabine-TBI (200 cGy) 5
Busulfan-Melphalan 2
Non-myeloablative
TBI (200 cGy) ± Fludarabine 75
TLI-ATG 4
GVHD prophylaxis
Cyclosporine+methotrexate 33
Cyclosporine+mycophenolate mofetil 84
Donor Type
Related 86
Unrelated 31
Stem cell source
Peripheral blood / Bone marrow 114 / 3
Patients previously treated with
anti-CD20 monoclonal antibody
18
RAEB indicates refractory anemia with excess of blasts; TBI, total
body irradiation; ATG, Antithymocyte globulin; TLI, total lymphoid
irradiation.
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LFT and viral DNA load of patients at high risk
were carried out monthly for the first 3 months, and
complete HBV serologic tests at 3 and 6 months post-
transplant or as clinically indicated. Complete HBV
serologic tests were carried out every 6 months in pa-
tients at low risk or at the onset of LFT abnormalities.
HBV reactivation inHBVcarriers was defined as an
HBV-DNA level higher than 20,000 IU/mL and in pa-
tients originally HBsAg negative as reemergence of
HBsAg (reverse seroconversion) after gradual loss of
anti-HBs antibodies [7]. Hepatitis flare was defined as
an increase of serum ALT levels higher than 1.5-fold
of baseline, with a significant viral breakthrough from
baseline (at least 20,000 IU/mL) [13-17]. Moreover,
during hepatitis flare, workup for differential diagnoses
of posttransplant hepatic complications included sero-
logic tests and polymerase chain reaction (PCR) assays
for hepatitis A virus, hepatitis C virus, cytomegalovirus,
Epstein-Barr virus, herpes simplex virus types 1 and 2,
human herpesvirus 6, parvovirus B19 and adenovirus;
serologic tests for aspergillum and toxoplasma; abdom-
inal ultrasound; drug toxicities, iron overload, and signs
and symptoms of graft-versus-host disease (GVHD)
and sinusoidal obstructive syndrome. Liver biopsy wasnot performed routinely [18]. Liver GVHD was diag-
nosed as per standard criteria [19,20] and defined as
LFT abnormalities (alkaline phosphatase $2  upper
limit of normal, AST or ALT.3 upper limit of nor-
mal or total serum bilirubin $1.6 mg/dL) not because
of other causes and responsive to immunosuppressive
drugs.
Statistical Analysis
Incidence of GVHD between patients exposed or
not exposed to HBV and incidence of hepatitis be-
tween patients treated with lamivudine or not treated
were compared by the Fisher’s Exact Test. Clinical
outcomes were calculated with the method of Ka-
plan-Meier and analyzed with the ‘‘log rank’’ test. Sta-
tistical analyses were obtained with the SPSS software
(SPSS Inc. and Microsoft Corporation, Chicago, IL).
A P value\.05 was considered statistically significant.RESULTS
Survival
Overall, after a median follow-up of 42 (range: 14-
111) months, 54 (46%) of the patients were alive,
whereas 31 (26%) died from disease progression, 27
(23%) from transplant-related toxicity, 2 (2%) from
a second malignancy, 1 (1%) of acute myocardial in-
farction. Median time to death was 9 months (range:
1-96). No HBV-related death was observed.
Liver GVHD and HBV
Among the 23 patients who developed grade II-III
acute liver GVHD (aGVHD), 1 had received the graft
from an HBsAg-positive donor, 1 was an HBsAg
positive patient, and 5 were anti-HBc positive. The
remaining 16 had no serologic evidence of prior
HBV exposure. Liver GVHD incidence was not influ-
enced by pretransplant HBV exposure (P5.6).
Lamivudine Prophylaxis, HBV Reactivation, and
Outcome
Eighty-seven patients at low risk of HBV reactiva-
tion were not given lamivudine prophylaxis and did not
develop hepatitis B. Of note, none of the 5 naı¨ve pa-
tients of this group who received a transplant from
anti-HBc positive donors experienced hepatitis, and
only 1 of the 5 became anti-HBc positive during
follow-up.
Among the 30 patients at high risk of HBV reacti-
vation (25 HBsAg negative/anti-HBc positive;
3 HBsAg negative from HBsAg positive donors;
2 HBsAg positive recipients), lamivudine prophylaxis
was given to the 16 who were transplanted in 2005 or
later, for a median duration of 19 months (range: 8–
42). The other 14 HBsAg negative/anti-HBc positive
Table 2. Virological characteristics and clinical outcome of high risk recipients
Prophylaxis No prophylaxis
No. of patients 16 14
Sex (Male/Female) 7/9 8/6
Age, years (range) 56 (29-64) 52 (40-63)
MM 6 / CLL 4 MM 10
Diseases AML-RAEB 3 AML-RAEB 3
NHL 1 / CML 1 CLL 1
CMML 1
Myeloablative conditioning 1 0
GVHD prophylaxis
CsA-MMF 9 14
CsA-MTX 7 0
Pre-transplant HBV serology No. of Patients No. of Patients
HBsAg + 2 0
Anti-HBc + 15 14
Anti-HBs + 10 7
HBV DNA (IU/mL) + 1 (19.500) 0
Post-transplant HBV serology
HBsAg + 1§ 2
Anti-HBc + 12 12
HBV-DNA (IU/mL) + 1§ (1.400.000) 2 (>108; 71.700)
HBV hepatitis 1§ 2
Median follow-up (range) 40 months (17-55) 85 months (59-111)
Alive 8 2
Donor HBV serology
HBsAg + 3 0
Anti-HBc + 7 3
Anti-HBs + 5 3
HBV-DNA (IU/mL) + 2 (121; 762) 0
HBV prophylaxis 0 0
MM indicates multiple myeloma; CLL, chronic lymphocytic leukemia; AML-RAEB, acute myelogenous leukemia-refractory anemia with excess of blasts;
NHL, non Hodgkin lymphoma; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; GVHD, graft-versus-host disease; CSA,
cyclosporine; MMF, mycophenolate mophetil; MTX, methotrexate; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; Anti-HBc, anti-hepatitis B
core antibodies; Anti-HBs, anti-hepatitis B surface antigen antibodies.
§developed after early lamivudine discontinuation.
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any prophylaxis.
Lamivudine was well tolerated in all but 1, who
discontinued the drug because of severe nausea.
Among these 16 patients, 3 died from disease progres-
sion during treatment. According to the scheduled
prophylaxis [7] and at the time of this analysis, lamivu-
dine has been stopped 12-18 months after the discon-
tinuation of all immunosuppressive drugs in 4 patients,
and, following the withdrawal, none of them experi-
enced HBV reactivation after a median time of 12
months (range: 1-19).
Three patients with HBsAg positive donors
(HBeAg, anti-HBe, and anti-HDV negative), of
whom 2 were also positive for HBV-DNA, were given
lamivudine and none developed HBV reactivation or
hepatitis (Table 3). During follow-up, all remained
HBsAg and anti-HBs negative, with undetectable
HBV-DNA, and only 1 became anti-HBc positive.
The 2 HBV-DNA-positive donors were treated for 1
month prior to transplant with lamivudine at 100
mg/day and became negative at the time of granulocyte
colony stimulating factor (G-CSF) mobilized periph-
eral blood stem cell (PBSC) collection. One recipient
developed liver aGVHD 24 months after transplant
and was still on immunosuppression and lamivudine
prophylaxis at the time of last contact; another discon-tinued all immunosuppressive drugs 13 months after
transplant and stopped lamivudine 13 months later
without any signs of HBV reactivation; finally, the
third recipient stopped immunosuppressive therapy
8 months posttransplant because of leukemic progres-
sion, and died from the disease 18 months posttrans-
plant while on lamivudine.
The 2 HBsAg positive recipients (HBeAg, anti-
HBe, and anti-HDV negative) became HBsAg nega-
tive 13 and 3 months posttransplant, respectively,
while on lamivudine (Table 3). One patient developed
mild liver GVHD 4 months posttransplant; neverthe-
less, discontinued all immunosuppression 6 months
posttransplant and lamivudine 15 months later, with-
out evidence of HBsAg reverse seroconversion,
whereas the other was still on prophylaxis at the time
of last contact.
Overall, 3 of 117 patients developed HBV hepati-
tis at 4, 15, and 29 months posttransplant, diagnosed
in the light of ALT levels and serology. All 3 patients
were anti-HBc positive and HBsAg negative before
transplant; their donors were HBsAg negative and
only 1 anti-HBc positive (Table 4). Two patients
were not given prophylaxis because transplanted
before 2005 and 1 discontinued it prematurely be-
cause of intolerance. The latter was HBsAg negative,
anti-HBc and anti-HBs positive, underwent 2
Table 3. Virological characteristics and clinical outcome of HBsAg positive/negative pairs
HBsAg negative recipients / positive donors HBsAg positive recipients / negative donors
Recipient 1 Recipient 2 Recipient 3 Recipient 4 Recipient 5
Sex Male Female Female Male Female
Age (years) 54 61 28 38 58
Disease MM AML CML MM MM
Myeloablative conditioning No No Yes No No
GVHD prophylaxis
CsA-MMF + 2 2 + +
CsA-MTX 2 + + 2 2
Pre-transplant recipient
HBV serology
HBsAg 2 2 2 + +
Anti-HBc 2 + + + +
Anti-HBs + + + 2 2
HBV-DNA (IU/mL) 2 2 2 2 19.500
HBV prophylaxis Yes Yes Yes Yes Yes
Post-transplant
recipient HBV
serology
HBsAg 2 2 2 2 2
Anti-HBc + + + + +
Anti-HBs + + + + +
HBV-DNA (IU/mL) 2 2 2 2 2
HBV hepatitis No No No No No
Follow-up (months) 43 18 40 26 35
Outcome Alive Dead  Alive Alive Alive
Donor HBV serology
HBsAg + + + 2 2
Anti-HBc + + + 2 +
Anti-HBs 2 2 2 + +
HBV-DNA (IU/mL) 2 121 762 2 2
Donor HBV prophylaxis No Yes Yes No No
HBsAg indicates hepatitis B surface antigen; MM, multiple myeloma; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; GVHD,
graft-versus-host disease; CsA, cyclosporine; MMF, mycophenolate mophetil; MTX, methotrexate; HBV, hepatitis B virus; Anti-HBc, anti-hepatitis B core
antibodies; Anti-HBs, anti-hepatitis B surface antigen antibodies.
 due to disease progression.
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positive donor for disease progression and was treated
with anti-CD20 monoclonal antibodies in between.
Lamivudine was given for 8 months from the time
of the first transplant up to 1 month postsecond trans-
plant. HBV reactivation (HBsAg positive, ALT 1205
IU/L, HBV DNA 1,400,000 IU/mL) occurred 7
months after lamivudine had been discontinued.
However, the drug was well tolerated when used for
treating HBV hepatitis.
Hepatitis was successfully treated in all with lami-
vudine at 100 mg/day though adefovir was added in 1
patient 16 months later because of biochemical and vi-
rologic breakthrough (ALT 87 U/L, HBV DNA
298,000 UI/mL) [11]. One patient died from disease
progression during maintenance treatment.
Overall, between patients given and not given lam-
ivudine, therewas no difference in overall survival (OS).DISCUSSION
HBV reactivation represents a well-known prob-
lem in hematologic malignancies. It is reported that
HBsAg positive patients with lymphoma, in particular,
are at higher risk of HBV reactivation after chemo-therapy [7,21,22]. In Italy, the prevalence of HBsAg
among these patients was reported as higher than 8%
[22], more than 7-fold the actual rate in the general
population (1%) [23]. A high prevalence of HBsAg
negative/anti-HBc positive status among patients
with non-Hodgkin lympohoma was also described
(41.5%) [22]. Furthermore, the increasing use of
intense myelosuppressive therapies, including trans-
plants and monoclonal antibodies [8,24,25], combined
with a profound immunodeficiency related to the un-
derlying disease [26-28], confer additional risks. De-
spite the fact that HBV reactivation has been
increasingly observed after allogeneic transplantation,
with an incidence of 50% or more for susceptible
individuals [29,30], very few data have been published
regarding the impact of RIC/NMA conditioning reg-
imens [8,9] and the role of prophylaxis with lamivudine
in HBsAg negative but anti-HBc positive patients [31].
Our retrospective analysis on 117 patients trans-
planted before and after the clinical introduction of
lamivudine showed interesting results as to the risk of
hepatitis B in ‘‘naı¨ve’’ and anti-HBc positive recipients,
the risk of transmission from anti-HBc positive donors,
and the efficacy of lamivudine in HBsAg positive or
anti-HBc positive recipients, and in recipients with
HBsAg positive donors.
Table 4. Virological characteristics and clinical outcome of Anti-HBc positive recipients (25 patients)
Prophylaxis (n511) NO Prophylaxis (n514)
Donor Anti-HBc POS
(n53)
Donor Anti-HBc NEG
(n58)
Donor Anti-HBc POS
(n53)
Donor Anti-HBc NEG
(n511)
Sex (M/F) 2 / 1 3 / 5 3 / 0 5 / 6
Median age (years) 56 (55 - 58) 56 (53 - 64) 56 (46 - 59) 55 (40 - 63)
MM 1 / AML 1 CLL 3 / MM 2 MM 7 / AML 3
Disease CLL 1 AML 1 MM 3 CLL 1
NHL 1 / CML 1
Myeloablative conditioning 1 0 0 0
GVHD prophylaxes
CsA-MMF 1 5 3 11
CsA-MTX 2 3 0 0
Recipient pre-transplant HBV serology
HBsAg + 0 0 0 0
Anti-HBc + 3 8 3 11
Anti-HBs + 1 6 1 7
HBV-DNA (IU/mL) + 0 0 0 0
Recipient post-transplant HBV serology
HBsAg + 1 0 0 2
Anti-HBc + 3 4 (2 NA) 1 (1 NA) 9
HBV-DNA (IU/mL) + 1 (1.400.000) 0 0 2 (>108; 71.700)
HBV hepatitis 1§ No No 2
Median follow-up (range) 47 months (41 - 54) 40 months (17 - 54) 111* months 59* months
Outcome
Alive 2 7 1 1
DRM / TRM 1 / 0 0 / 1 2 / 0 3 / 4
Other death causes 0 0 0 3
Donor HBV serology
HBsAg + 0 0 0 0
Anti-HBc + 3 0 3 0
Anti-HBs + 2 1 3 0
HBV-DNA (IU/mL) + 0 0 0 0
Donor HBV prophylaxis No No No No
Anti-HBc indicates anti-hepatitis B core antibodies; MM, multiple myeloma; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia;
CML, chronic myelogenous leukemia; NHL, non Hodgkin lymphoma; GVHD, graft-versus-host disease; CsA, cyclosporine; MMF, mycophenolate mo-
phetil; MTX, methotrexate; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; Anti-HBs, anti-hepatitis B surface antigen antibodies; NA, not
available; DRM, disease related mortality; TRM, treatment related mortality.
§Developed after early lamivudine discontinuation.
*Only one patient evaluable.
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tions in anti-HBc positive patients and, though infre-
quent, in HBV serum marker-negative individuals in
the Italian general population. In hematologic
patients, it is unknown whether the complete absence
of HBV serum markers in recipients could be ascribed
to a gradual and progressive disappearance of
antibodies, because of the disease-related immunosup-
pression, to a real naı¨ve condition for all viral markers
susceptible of a new infection posttransplant or to an
occult HBV infection [32].
In the setting of liver transplantation, a posttrans-
plant risk of hepatitis B has been shown in naı¨ve recipi-
ents with anti-HBc positive donors, whereas reports in
allogeneic SCT are scarce [7]. In our experience, naı¨ve
patients did not receive prophylactic lamivudine and
did not develop hepatitis B during follow-up, indicating
no risk of clinical reactivation.Moreover, no hepatitis B
was observed in the 5 naı¨ve recipients with anti-HBc
positive donors. However, we observed that 1 HBV
serum marker-negative patient with an anti-HBc posi-
tive donor developed anti-HBc antibodies after trans-
plant without evidence of HBV reactivation. Theappearance ofHBVmarkers in originally naı¨ve patients
has alreadybeendescribed after solidorgan transplanta-
tion, sometimes with a short detectable HBV viremia
without clinical evidence of hepatitis [33,34]. Thus, in
our patient, it is not possible to determine if the
appearance of anti-HBc antibodies followed a pretrans-
plant occult infection [13] or this immunity was trans-
ferred from the donor.
In a multicenter study on 2586 transplant patients
not given prophylactic lamivudine, only 24 (0.9%)
donors wereHBsAg positive; however, 22%of the orig-
inally pretransplant HBsAg negative recipients with
HBV carrier donors seroconverted after transplant [2].
In our experience, lamivudine was administered to 3 re-
cipients who received the graft from HBsAg positive
donors and to 2 donors with detectable HBV-DNA.
The lack of viral reactivation suggests the efficacy of
lamivudine in abating donor pretransplant viral load
and in preventing posttransplant HBV reactivation in
the recipients. Similarly, Hui et al. [35] retrospectively
compared 29 recipients treated with booster doses of
HBV vaccine and lamivudine to 25 historic controls
who received no prophylaxis. The study demonstrated
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being able to differentiate the role of HBV vaccination
from that of lamivudine.
The efficacy of lamivudine in HBsAg positive re-
cipients undergoing an allograft has been supported
in 3 recent meta-analyses [5,6,36], which showed a sta-
tistically significant difference in the incidence of HBV
reactivation and mortality between patients treated
with lamivudine and the control group. In our study,
lamivudine was given to 2 patients with detectable
HBsAg. Interestingly, both patients received the graft
from anti-HBs positive donors and became HBsAg
negative with no signs of HBV reactivation.
In occult HBV carriers with isolated anti-HBc an-
tibodies, viral replication has been shown to persist in
the liver and in peripheral blood mononuclear cells
[37,38]. In the setting of allografting, immunosup-
pression and loss of the patient B and T cell reper-
toires may lead to viral reactivation, with the
reappearance of HBsAg after gradual loss of anti-
HBs, defined as reverse seroconversion. Its incidence
has been described to be up to 50% [1,39,40]. More
recently, HBV reactivation in occult carriers has
been reported also in a patient receiving an autograft
followed by bortezomib, and in 5 of 17 allotransplant
patients positive for anti-HBc, but not in 38 negative
prior to transplant [31]. Furthermore, the availability
of new, potent immunosuppressive drugs like the
anti-CD20 and the anti-CD52 monoclonal anti-
bodies, recently introduced in treatment plans, has
further increased the risk of HBV reactivation in pa-
tients with hematologic malignancies [8,24,25,37,41].
Nevertheless, there are still some controversies about
the use of prophylaxis in this setting. In our report,
among 25 patients with anti-HBc antibodies, reverse
seroconversion and hepatitis B were not observed in
patients treated with lamivudine, whereas hepatitis B
developed in 3 of the untreated patients (including 1
patient who prematurely discontinued the drug be-
cause of intolerance). These results are suggestive of
a protective role of lamivudine in this setting. Indeed,
our findings should be confirmed on a larger series of
patients. Interestingly, all reverse seroconversions
and hepatitis B occurred in patients prepared for
transplant with an RIC or an NMA conditioning.
This observation indicates that a less myelosuppres-
sive conditioning regimen does not confer protection
against HBV reactivation. This may be explained by
a number of reasons such as patient older age and
heavy pretreatments, the use of highly immunosup-
pressive agents (ie, fludarabine) in the conditioning
regimen and the prolonged posttransplant immuno-
suppression. In a similar setting, the efficacy of HBV
vaccine 1 year after the discontinuation of the post-
transplant immunosuppression has also been reported.
However, about half of the patients evaluated were not
eligible for vaccination, and the incidence of reverseseroconversion in vaccinated patients was similar to
that of the historic control [42].
Given that among the 16 patients receiving lami-
vudine prophylaxis for a median of 19months none de-
veloped reverse seroconversion or hepatitis, we assume
that the efficacy of lamivudine was maintained during
the entire follow-up. When lamivudine prophylaxis
was started, HBV-DNA was undetectable in all but 1
patient. Interestingly, Hsiao and colleagues [43] evalu-
ated the impact of lamivudine resistance in 16 patients
with detectable HBV-DNA at the time of autologous
or allogeneic transplantation. Despite the extensive
use of lamivudine and the emergence of mutations in
63% of the patients, no deaths were related to HBV
reactivation or severe HBV hepatitis. With the new
potent antiviral drugs [44], lamivudine may be prefer-
able for prophylaxis, where resistance may be a rare
event, rather than for treatment of HBV hepatitis.
Optimal duration of lamivudine prophylaxis re-
mains to be determined. In our setting, we considered
lamivudine discontinuation only in patients at least 12-
18 months after all immunosuppression was stopped
and with no signs of HBV reactivation. The need of
prolonged treatment even in patients off immunosup-
pressive drugs may have been confirmed by our obser-
vation of an HBV reactivation 18 months after the
discontinuation of immunosuppression. Overall, in 5
patients who had discontinued prophylaxis at the
time of our analysis, hepatitis had occurred only in
the 1 who had developed intolerance to lamivudine
and prematurely interrupted prophylaxis.
Finally, we did not observe a correlation between
previous exposure to HBV and development of liver
GVHD.
In conclusion, viral reactivation or hepatitis B after
allogeneic SCT were not observed in HBV naı¨ve recip-
ients, transplanted fromHBsAg negative/anti-HBc pos-
itive or negative donors. Lamivudine was effective in
controlling reactivation in: HBsAg positive recipients,
in patients transplanted from HBsAg positive donors
and in HBsAg negative/antiHBc positive recipients.
Furthermore, our findings indicate a significant risk in
HBsAg negative/anti-HBc positive recipients in the
absence of prolonged prophylaxis.ACKNOWLEDGMENTS
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